Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.67 |
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16638274 | 1.00 | GLP1R (0.67) | GLP1RNOD1FOLH1FNTAFNTB | |
| SCHEMBL16947959 | 1.00 | GLP1R (0.67) | GLP1RNOD1FOLH1FNTAFNTB | |
| SCHEMBL15357538 | 1.00 | GLP1R (0.67) | GLP1RNOD1FOLH1FNTAFNTB | |
| SCHEMBL24891117 | 1.00 | GLP1R (0.67) | GLP1RNOD1FOLH1FNTAFNTB | |
| SCHEMBL16947828 | 1.00 | GLP1R (0.67) | GLP1RNOD1FOLH1FNTAFNTB | |
| SCHEMBL24890886 | 1.00 | GLP1R (0.67) | GLP1RNOD1FOLH1FNTAFNTB | |
| SCHEMBL21243001 | 0.99 | GLP1R (0.66) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL14438782 | 0.94 | GLP1R (0.74) | GLP1RNOD1 | |
| SCHEMBL24249859 | 0.93 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL24249840 | 0.93 | GLP1R (0.68) | GLP1RNOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165313-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2020-05-28 | — | — | US | disclosed |
| US-9006178-B2 | Double-acylated GLP-1 derivatives with a linker | NOVO NORDISK A/S (DK) | 2015-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165313-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | EGFR, VEGFA, ERBB2 | GLP1R 30/4885NOD1 4450/4885FOLH1 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.